COMMUNIQUÉS West-GlobeNewswire

Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018

06/11/2018 - 13:00

Retrospective Analysis Revealed Clinically Meaningful Response to Tonmya® in Female PTSD Participants Overall and for Non-Combat-Related Traumas Experienced Within Nine Years Prior to Screening Results from Phase 3 P301 [...]

GW Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results and Host Conference Call on 27 November, 2018

06/11/2018 - 13:00

LONDON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its [...]

Antares Pharma Reports Third Quarter 2018 Operating and Financial Results

06/11/2018 - 13:00

The Company Posts Record Quarterly Revenue Of $17.9 Million EWING, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company) today announced operating and financial results for the third [...]

BioCryst Reports Third Quarter 2018 Financial Results

06/11/2018 - 13:00

APeX-2 study enrollment completed, results on-track for Q2 2019 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the [...]

Imprimis Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 13, 2018

06/11/2018 - 13:00

SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today announced it will release third quarter 2018 financial results after the close of trading on Tuesday, November 13, 2018. [...]

Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants

06/11/2018 - 13:00

Proceeds Expected to be Sufficient to Fund Company’s Liberatus Phase 3 Clinical Trial for RP-G28 for Lactose Intolerance Through Announcement of Top-Line Data Anticipated in the Second Half of 2019 LOS ANGELES, Nov. 06 [...]

Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences

06/11/2018 - 13:00

GAITHERSBURG, Md., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences [...]

Neuronetics Reports Third Quarter 2018 Financial and Operating Results

06/11/2018 - 13:00

MALVERN, Pa., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for [...]

Managers’ transactions

06/11/2018 - 12:58

Company Announcement No. 20/2018 November 6, 2018 For further information please contact: Martin Riise, Senior Director, Investor Relations, Tel: +45 5339 2250 Camilla Lercke, Head of Media Relations, Tel: +45 5339 2384 [...]

Cellular Biomedicine Group Reports Third Quarter Financial Results and Recent Business Highlights

06/11/2018 - 12:56

Debuted its next 12-18 months’ immuno-oncology clinical development programs for both hematologic malignancies and solid tumors to key opinion leaders, investment and industry executives Licensed patents from the [...]

Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events

06/11/2018 - 12:50

CONSHOHOCKEN, Pa., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2018 financial results and described upcoming clinical events: “Madrigal made important [...]

Loxo Oncology to Participate in Upcoming Investor Conferences

06/11/2018 - 12:45

STAMFORD, Conn., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that [...]

Tetra Bio-Pharma Enters into Non-Binding Proposal to Acquire Panag Pharma Inc.

06/11/2018 - 12:30

The Proposed Transaction is expected to provide Tetra: With the most robust Pharmaceutical and Natural Health Products (NHP) pipeline of any Cannabinoid company; With more pharmaceutical and natural health products; The [...]

ChromaDex Appoints Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation

06/11/2018 - 12:30

LOS ANGELES, Nov. 06, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Matthew Roberts as Chief Scientific Officer and Senior Vice President of Innovation, effective [...]

Syneos Health Reports Third Quarter 2018 Results

06/11/2018 - 12:20

Highlights GAAP total revenue of $1.11 billion and $3.24 billion for the three and nine months ended September 30, 2018, respectively. Combined Company ASC 606 adjusted service revenue of $1.12 billion and $3.26 billion [...]

Tabula Rasa HealthCare Announces Third Quarter 2018 Operating Results

06/11/2018 - 12:00

Third Quarter 2018 Revenue of $54.4 million, growth of 66%; 2018 Revenue Guidance Increased MOORESTOWN, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ:TRHC), a healthcare [...]

HealthLynked Corp. Announces the Addition of Dr. Maher Albitar to its Scientific Advisory Board

06/11/2018 - 12:00

NAPLES, Fla., Nov. 06, 2018 (GLOBE NEWSWIRE) -- HealthLynked Corp. (OTCQB: HLYK) today announced that Maher Albitar M.D. will be joining the company’s Scientific Advisory Board (SAB). HealthLynked is an innovative [...]

EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments

06/11/2018 - 12:00

-YUTIQ ™ approved by U.S. FDA; anticipated launch in calendar 1Q19- -Exclusive license granted to Ocumension Therapeutics to develop and commercialize EyePoint’s three-year micro-insert product using the Durasert™ [...]

Invitation: Terveystalo Plc Q3 result - webcast and conference call on 14 November 2018

06/11/2018 - 09:37

Terveystalo Plc will publish its Interim report for January-September 2018 on 14 November at 9:00 EEST. (Finnish time). The English live webcast and conference call will be held on 14 November at 11:30 Finnish time ( [...]